CA Patent

CA2542481A1 — Imidazopyrazine tyrosine kinase inhibitors

Assigned to OSI Pharmaceuticals LLC · Expires 2005-04-28 · 21y expired

What this patent protects

Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine ki…

USPTO Abstract

Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2542481A1
Jurisdiction
CA
Classification
—
Expires
2005-04-28
Drug substance claim
No
Drug product claim
No
Assignee
OSI Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.